PHLPP2与Akt表达对NSCLC紫杉醇耐药的临床意义

Clinical significance of PHLPP2 and Akt expression on paclitaxel resistance of NSCLC

目的研究PHLPP2在紫杉醇耐药非小细胞肺癌组织中的表达及其与Akt表达的关系。方法采用免疫组化方法分别检测160例非小细胞肺癌组织中的PHLPP2、Akt表达,分析PHLPP2在紫杉醇耐药组和非耐药组非小细胞肺癌组织细胞中的表达高低及其与Akt表达的关系。结果(1)PHLPP2在低中分化肺癌组织内的阳性表达为39.8%,高分化肺癌组织内的阳性表达为70.2%,两者表达存在显著性差异(χ^2=13.539,P<0.001)。(2)Akt在Ⅳ期的阳性表达为77.0%,在Ⅲb期的阳性表达为56.7%,两者表达存在显著性差异(χ^2=7.297,P<0.05)。在淋巴结转移的阳性表达为83.3%,在无淋巴结转移的阳性表达为44.8%,两者表达存在显著性差异(χ^2=25.804,P<0.001)。在不同的分化程度、性别、年龄、肿瘤最大直径、组织学类型的表达差异均无显著性(P>0.05)。(3)PHLPP2表达在TP方案耐药组中低表达率高于非耐药组,差异有统计学意义(P=0.043)。(4)Akt表达在TP方案耐药组中高表达率高于非耐药组,差异有统计学意义(P=0.022)。结论PHLPP2可能通过调节Akt水平减少NSCLC对紫杉醇治疗的耐药性。

Objective To study the expression of PHLPP2 in paclitaxel-resistant non-small cell lung cancer and its relationship with Akt expression. Methods Immunohistochemistry was used to detect the expression of PHLPP2 and Akt in 160 non-small cell lung cancer tissues. The expression of PHLPP2 in paclitaxel-resistant and non-resistant NSCLC tissues, and its relationship with the expression of Akt were analyzed. Results (1)The positive expression of PHLPP2 was 39.8% in poor and middle-differentiated lung cancer tissues, and 70.2% in well-differentiated lung cancer tissues. There was significant difference between the two expressions(χ^2=13.539, P<0.001).(2)The positive expression of Akt in the stage Ⅳ group was 77.0%, and the positive expression in the stage Ⅲb group was 56.7%. There was a significant difference between the two groups(χ^2=7.297, P<0.05). The positive expression of Akt was 83.3% in the lymph node metastasis group and 44.8% in the no lymph node metastasis group. There was a significant difference between the two groups(χ^2=25.804, P<0.001). There were no significant differences in tumor maximum diameter and the expression levels of histological type between different differentiation groups, gender groups, age groups(P>0.05).(3)The low expression rate of PHLPP2 expression in the TP regimen resistant group was higher than that in the non-resistant group (P=0.043).(4) The high expression rate of Akt expression in the TP regimen resistant group was higher than that in the non-resistant group, with significant difference(P=0.022). Conclusion PHLPP2 may reduce the resistance of NSCLC to paclitaxel treatment by regulating Akt levels.